A new partnership is consolidating tissue oxygenation data, bacterial imaging, and calibrated graft sizing into one wound care platform, giving clinicians an objective record of treatment decisions.
Clinicians using advanced modalities are being asked to prove the value of every application, and they deserve tools that make that easy.”— Pierre Lemire, CEO, Kent Imaging
CALGARY, AB – ALBERTA, CANADA, October 14, 2026 /EINPresswire.com/ — Kent Imaging Inc., a global leader in advanced imaging solutions for wound and surgical care, today announced a partnership with TrueGraft to integrate their wound measurement and graft sizing technology into Kent Imaging's Snapshot platform. The collaboration will bring objective tissue assessment and precise, calibrated wound sizing together in a single platform, giving clinicians a unified record of what they treated, why they treated it and how much product they used.
“Having TrueGraft available alongside Kent Imaging’s devices gives my team objective, real-time insight at the point of care, which helps us make more informed treatment decisions,” stated Dr. Shaun Carpenter, Chief Executive Officer of MedCentris. “I see this partnership as a meaningful step toward better outcomes in wound care.”
Also worth a look: The Business Research Company forecasts drivetrain vibration sensor market to hit $2.69B by 2030 and Glīd Technologies returns to Disrupt with Stōrm, a hybrid freight platform with 10x the power.
Advanced wound care modalities, including skin substitutes and cellular and tissue-based products (CAMPs), are facing heightened payer and regulatory scrutiny. Every treatment decision needs to be supported by clear clinical rationale, accurate measurement and documentation that holds up to review. Yet in many practices those data points live in different devices, different systems and sometimes on paper, making it harder to tell a complete and consistent story about each patient.
The Kent Imaging and TrueGraft partnership will address that gap. TrueGraft delivers a standardized, calibrated approach to wound measurement and graft sizing designed to reduce gross inaccuracies in product selection and account for discarded material. Kent Imaging's SnapshotNIR provides real-time tissue oxygenation mapping, and SnapshotGLO visualizes the fluorescence associated with harmful bacteria in and around a wound at the point of care. Connected through single platform, these capabilities support each step of an advanced modality decision.
"Clinicians using advanced modalities are being asked to prove the value of every application, and they deserve tools that make that easy," said Pierre Lemire, CEO of Kent Imaging. "Bringing TrueGraft's precision sizing into the Snapshot platform means a single, objective record that shows why a product was chosen, how it was sized, and how the wound responded. That is what makes advanced wound care defensible, and it is a platform that can scale with our customers."
About Kent Imaging
Based in Calgary, Alberta, Canada, Kent Imaging is a leading innovator in advanced imaging technology. The company designs, manufactures, and markets medical devices that support real-time decision-making in wound care, vascular, and surgical specialties. Through patented technologies, Kent continues to deliver groundbreaking solutions that support healthcare systems around the world.
The Snapshot product suite now includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025; and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect—promoting treatment consistency, supporting improved workflow, and contributing to better patient care worldwide. www.kentimaging.com
SnapshotGLO® is a registered trademark of Kent Imaging Inc.
SnapshotNIR® is a registered trademark of Kent Imaging Inc.
About TrueGraft
TrueGraft, LLC builds wound measurement, product sizing, and documentation software for wound care clinics. Clinicians photograph the wound with a calibration card, trace and confirm the wound boundary, and record depth, undermining, and tunneling. TrueGraft builds a three-dimensional model of the wound bed from those measurements and sizes the clinician-selected skin substitute to the therapeutic treatment area, including multi-piece layouts that cut discarded material. Each encounter closes with an Audit Note that records the measurement method, each graft applied by lot number, the documented discard, and the Medicare coverage policy that applies to the visit. TrueGraft exists to make wound healing measurable. For more information, visit www.truegraft.com.
Leah Pavlick
Kent Imaging Inc.
leah@kentimaging.com
Visit us on social media:
LinkedIn
Why it matters: By merging imaging data with calibrated sizing and documentation, this partnership directly addresses the growing payer and regulatory demands for objective evidence in advanced wound care, potentially streamlining reimbursement and improving consistency in treatment decisions.
